investorscraft@gmail.com

Intrinsic Value of Amphastar Pharmaceuticals, Inc. (AMPH)

Previous Close$23.20
Intrinsic Value
Upside potential
Previous Close
$23.20

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Amphastar Pharmaceuticals, Inc. operates in the specialty pharmaceutical sector, focusing on the development, manufacturing, and commercialization of generic and proprietary injectable, inhalation, and intranasal products. The company’s revenue model is driven by a diversified portfolio of products, including critical care medications and biosimilars, catering to hospitals, clinics, and retail pharmacies. Amphastar has carved a niche in complex generics, leveraging its expertise in drug delivery systems to address unmet medical needs. Its market position is strengthened by vertical integration, with in-house manufacturing capabilities ensuring cost efficiency and supply chain resilience. The company competes in a highly regulated environment, where differentiation through R&D and regulatory expertise is key. Amphastar’s strategic focus on high-barrier-to-entry products mitigates pricing pressures common in the generics market, positioning it for sustainable growth.

Revenue Profitability And Efficiency

Amphastar reported revenue of $712.8 million for FY 2024, with net income of $159.5 million, reflecting a net margin of approximately 22.4%. Diluted EPS stood at $3.06, demonstrating robust profitability. Operating cash flow was $213.4 million, underscoring efficient cash generation. Capital expenditures of $41.0 million indicate disciplined reinvestment, aligning with growth initiatives without compromising liquidity.

Earnings Power And Capital Efficiency

The company’s earnings power is evident in its ability to convert revenue into net income at a healthy margin. With operating cash flow significantly exceeding net income, Amphastar exhibits strong capital efficiency. Its focus on high-margin products and operational leverage supports sustained earnings growth, while prudent capex allocation ensures optimal returns on invested capital.

Balance Sheet And Financial Health

Amphastar’s balance sheet shows $151.6 million in cash and equivalents against total debt of $650.5 million, indicating a leveraged but manageable position. The debt level reflects strategic investments in growth, supported by consistent cash flow generation. The absence of dividends suggests a focus on reinvestment and debt reduction, aligning with long-term financial stability.

Growth Trends And Dividend Policy

Revenue growth trends highlight Amphastar’s successful product launches and market expansion. The company does not currently pay dividends, prioritizing internal growth opportunities and debt management. Future dividend potential may emerge as cash flows stabilize, but the current strategy emphasizes capital appreciation through reinvestment.

Valuation And Market Expectations

Trading at a diluted EPS of $3.06, Amphastar’s valuation reflects market confidence in its niche positioning and growth trajectory. Investors likely anticipate continued margin expansion and pipeline-driven revenue growth, pricing in the company’s ability to navigate regulatory and competitive challenges.

Strategic Advantages And Outlook

Amphastar’s vertical integration and focus on complex generics provide a competitive edge. The outlook remains positive, driven by R&D investments and regulatory approvals. Risks include pricing pressures and pipeline delays, but the company’s strategic execution positions it well for sustained performance in the specialty pharma landscape.

Sources

10-K filing, CIK 0001297184

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount